title: [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
abstract: To evaluate the efficacy and safety of interferon-alpha-2b (IFN-α-2b) in polycythemia vera patients(PV patient) with or without post-polycythemic myelofibrosis (post-PV MF), 30 patients with mutated JAK2V617F were enrolled in this study, from which 29 patients were evaluable. The percentage of mutated JAK2V617F allele (V617F%) was evaluated by real-time polymerase chain reaction (RT-PCR) before and after treatment with IFN-α-2b. The correlation of V617F allele burden with the major clinical outcomes was studied. Adverse effects appeared in patients was observed. The results showed that the median follow-up was 24 (12 - 42) months for 29 evaluable patients. Complete hematologic response was achieved in 10%, 48%, 72% and 78% of patients after treatment for 6, 12, 24 and 36 months respectively. The detection of V617F allele burden revealed that the molecular remission of patients (V617F%) was achieved in 41%, 76%, 89% and 89% after treatment for 6, 12, 24 and 36 months respectively. Molecular complete remission (JAK2V617F undetectable) was achieved in 4 patients, lasted from 6 to 12 months after IFN-α-2b discontinuation. The decrease of V617F% in patients with post-PV MF was significantly higher than that in patients without post-PV MF (53 ± 18% vs 32 ± 22%, respectively; p = 0.031) after treatment for 12 months. PV patients had a good tolerance to IFN-α-2b. It is concluded that IFN-α-2b can decrease the mutated V617F allele burden. Patients with PV, especially with post-PV MF, can achieve molecular remission after treatment with IFN-α-2b.
authors.affiliation: Chinese Academy of Medical Sciences, Tianjin 300020, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Bai
authors.forename: Yang-Ping
authors.initials: YP
authors.lastname: Xue
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Chun-Hua
authors.initials: CH
authors.lastname: Li
authors.forename: Dong-Mei
authors.initials: DM
authors.lastname: Fan
authors.forename: Bin
authors.initials: B
authors.lastname: Li
authors.forename: Shi-Cai
authors.initials: SC
authors.lastname: Xu
authors.forename: Da-Peng
authors.initials: DP
authors.lastname: Li
authors.forename: Xiu-Juan
authors.initials: XJ
authors.lastname: Sun
authors.forename: Bo
authors.initials: B
authors.lastname: Jiang
authors.forename: Ren-Chi
authors.initials: RC
authors.lastname: Yang
mesh_terms: D000328:Adult; D000483:Alleles; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C507924:JAK2 protein, human; D053614:Janus Kinase 2